A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Cancer Clinical Trial

Official title:

A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05378425
• Other study ID #: NTX 1088-01
• Secondary ID: KEYNOTE-E92MK-34
• Status: Recruiting
• Phase: Phase 1
• Start date: September 1, 2022
• Est. completion date: December 2025

Study information

• Verified date: February 2023
• Source: Nectin Therapeutics Ltd
• Contact: Keren Paz, PhD
• Phone: 201-218-1774
• Email: keren[@]nectintx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).

Description:

This is a Phase 1, open-label, multi-center study whose principal Part 1 stage objective is to determine the recommended Phase 2 dose (RP2D) of the anti-PVR monoclonal antibody (mAb) as a single agent and combined with the anti-PD-1 mAb pembrolizumab in patients with advanced solid malignancies.

In the Part 2 stage, the antitumor activity of NTX-1088 alone or combined with pembrolizumab will be evaluated in patients with malignancies known to express PVR.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologic or cytologic evidence of an advanced (locally advanced or metastatic) malignant solid cancer known to express PVR, or if the patient's cancer has been documented to express PVR.

2. Must have disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy in the physician's judgment likely to result in clinical benefit, or if such therapy has been refused by the patient.

3. Tumor tissue or paraffin block, ideally from the patient's most recent biopsy within 1 year of study treatment. A fresh tumor biopsy will be obtained if archival samples are not available or from tumor sampled more than 1 year prior to enrollment. Patient must be amenable to on treatment biopsy.

4. Disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

5. A least 18 years old.

6. An Eastern Cooperative Oncology Group (ECOG) performance status of =1.

7. Adequate baseline hematopoietic, kidney and liver function.

8. A left ventricular ejection fraction (LVEF) = 45%.

9. Female participants are eligible to participate if not pregnant, not breastfeeding, and must agree to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.

10. Male subjects must agree to follow contraceptive guidance during the study period and for at least 120 days after the last dose of study treatment.

11. Patient must give informed written consent for the study.

12. Patient must adhere to the study visit schedule and other protocol requirements.

13. Patient has sufficient venous access for protocol defined plasma/blood sampling.

Exclusion Criteria:

1. The patient was discontinued from prior treatment with an immuno-oncology therapeutic due to a Grade 3 or higher immune-related adverse event.

2. Received radiotherapy within 2 weeks of treatment.

3. Received radiation therapy to the lung that is greater than 30 Gray within 6 months of the first dose of study medication.

4. The patient is concurrently receiving treatment with anticancer therapies (cytotoxic chemotherapy, monoclonal antibodies, and/or small molecule tyrosine kinase inhibitors).

5. Received an allogeneic tissue/solid organ transplant.

6. Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.

7. Received prior treatment with NTX-1088 or another investigational agent targeting PVR.

8. The participant must have recovered adequately from any major surgery and/or any complications from the surgery prior to starting study intervention.

9. Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.

10. The patient must have recovered from all AEs due to previous therapies to Grade =1 or baseline.

11. The patient has an active autoimmune disease that required systemic treatment in the past.

12. Presence of an uncontrolled endocrine disorder.

13. Presence of clinically significant cardiovascular disease.

14. History of (non-infectious) pneumonitis or interstitial pulmonary disease that required steroids or has current pneumonitis or interstitial pulmonary disease.

15. Presence of uncontrolled, clinically significant pulmonary disease.

16. A previous severe hypersensitivity reaction (Grade =3) to pembrolizumab and/or any of its excipients.

17. A diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.

18. An uncontrolled intercurrent illness that would limit compliance with study requirements.

19. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with participation in the study.

20. A positive status for human immunodeficiency virus (HIV).

21. A known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA detected) infection.

22. Oxygen dependent.

23. The patient has any medical condition which, in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicities.

24. Additional active malignancy that is progressing or has required active treatment within the past 3 years.

25. Known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable.

26. Patient is pregnant or breast feeding.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Cancer
• Locally Advanced Solid Tumor
• Metastatic Cancer
• Neoplasm Metastasis
• Neoplasms
• Tumor, Solid

Intervention

Drug:
• NTX-1088
IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
• Pembrolizumab
IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).

Locations

Country	Name	City	State
Israel	Hadassah Medical Center	Jerusalem
Israel	Sheba Medical Center	Ramat Gan
United States	City of Hope	Duarte	California
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Ochsner Clinic Foundation	New Orleans	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Nectin Therapeutics Ltd	Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting Toxicity (DLT)	The incidence of DLTs during the DLT assessment period.	First 21 days of treatment.
Primary	Dose-Finding	Determination of the MTD or maximum tested dose, and the RP2D.	Screening to 30 days from last dose.
Primary	Frequency and Severity of Adverse Events (AE)	The incidences and percentages of patients experiencing AEs summarized by NCI CTCAE version 5.0 grade and by causality.	Screening to 30 days from last dose.
Secondary	Pharmacokinetics of NTX-1088	Maximum Plasma Concentration (Cmax)	Day 1 of dosing through 21 days post last dose.
Secondary	Pharmacokinetics of NTX-1088	Area Under the Curve (AUC)	Day 1 of dosing through 21 days post last dose.
Secondary	Objective Response Rate (ORR)	ORR according to RECIST v1.1.	Day 1 of dosing through 90 days after the last dose.
Secondary	Duration of Response (DoR)	Time from the date measurement criteria are first met for PR or CR to the date measurement criteria are first met for progressive disease.	Day 1 of dosing through 90 days after the last dose.
Secondary	Progression Free Survival (PFS)	Time from the date of initiation of study therapy to the date measurement criteria are first met for progressive disease or death from any cause, whichever occurs first.	Day 1 of dosing through 90 days after the last dose.
Secondary	Overall Survival (OS)	Time from the date of initiation of study therapy to the date of death from any cause.	Day 1 of dosing through 90 days after the last dose.